With its scale and IT skills, Parexel is well positioned to capitalize on an improving market.
Covance is positioning itself to be a one-stop shop for all of its clients' needs.
ICON's scale and unique operating model have propelled it to the top ranks of its industry.
Managed-care organizations are wielding more clout in contract negotiations, as LabCorp and Quest are increasingly forced to face off against each other for exclusive contracts.The company may find Medicare price increases hard to come by, as the government looks to rein in health-care
Quest Diagnostics' DGX third-quarter results were largely consistent with our expectations, and we are leaving our fair value estimate unchanged. Despite continued declines in employer drug testing revenue that drove total quarterly testing volume down 1.7%, Quest's gene-based and more complex test
Pharmaceutical Product Development PPDI reported third-quarter results that roughly fell in line with our expectations. Although management issued a dreary outlook for the remainder of 2009, we believe PPD's troubles to be temporary and do not anticipate any changes to our fair value estimate. The
Inverness Medical Innovations IMA reported strong third-quarter results that topped our expectations. Given this outperformance, we will reassess our near-term assumptions and probably raise our fair value estimate. Revenue rose to $536 million during the quarter, an increase of 22% from the